Lıver autoantıbodıes ın patients with osteoporosis Demirdal US et al. group for this study. In addition, there were no similar studies to compare our findings. Notwithstanding, the percentage of patients with positive autoantibodies may be significant. On the other hand, these findings could also attributed to normal variables or could be considered as coincidental. Studies with larger sample sizes may help us to elucidate the clinical importance of our findings. The second limitation of the study is adapting our findings to clinical practice. Our results may not be generalized, and similar studies are required to determine whether labora- tory testing should include autoantibodies as a marker of secondary causes of OP. Finally, the sample size is relatively small – the population of the study was derived from a single academic center– whereas OP is a widespread disease. Furthermore, our exclusion of subjects ineligible to participate in the study may have caused a smaller sample size than hoped. CONCLUSIONS This study assessed the presence of definite autoantibo- dies related with ALD in patients with OP. Regardless of the most frequently detected antibody-ANA in the present study, the presence of LMA, LSP, and anti-LKM1 has permitted us to see there may be some suspicious clues of ALD in patients with OP as a secondary risk factor. On the other hand, the clinical importance of the detected auto- antibodies is unclear. There is a need for comprehensive studies with a larger sample size and a design to compare the results with normal population to understand if the findings are normal variability or coincidental. REFERENCES 1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 1994. Geneva: WHO Study Group. Technical Report 843. 2. Keen R. Osteoporosis: Strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007; 21:109–22, doi: 10.1016/j.berh.2006.10. 004. 3. Wilkins CH. Osteoporosis screening and risk management. Clin Interv Aging. 2007;2:389–94. 4. Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y, et al. Disability after clinical fracture in postmenopausal women with low bone density: The fracture intervention trial (FIT). Osteoporos Int. 2003;14:69–76, doi: 10.1007/s00198-002-1314-y. 5. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38– 42, doi: 10.1007/s00198-003-1490-4. 6. Ethgen O, Tellier V, Sedrine WB, De Maeseneer J, Gosset C, Reginster JY. Health-related quality of life and cost of ambulatory care in osteoporosis: How may such outcome measures be valuable information to health decision-makers and payers? Bone. 2003; 32:718–24, doi: 10.1016/S8756- 3282(03)00089-9. 7. Satomi E, Sitta Mdo C, Machado AN, Garcez Leme LE. Identification and treatment of osteoporosis among elderly patients with hip fractures. Clinics. 2009;64:1201-4, doi: 10.1590/S1807-59322009001200010. 8. Odabası E, Turan M, Tekbas F, Kutlu M. Evaluation of secondary causes that may lead to bone loss in women with osteoporosis: A retrospective study. Arch Gynecol Obstet. 2009;279:863–7, doi: 10.1007/s00404-008- 0846-6. CLINICS 2010;65(10):971-974 9. Lash RW, Nicholson JM, Velez L,Van Harrison R, McCort J. Diagnosis and management of osteoporosis. Prim Care. 2009;36:181-98, doi: 10. 1016/j.pop.2008.10.009. 10. Sikon AL, Thacker HL, Carey J, Deal C, Licata AA. Secondary osteoporosis: Are we recognizing it? J Womens Health (Larchmt). 2006;15:1174–83, doi: 10.1089/jwh.2006.15.1174. 11. Leslie WD, Bernstein CN, Leboff MS; , American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–66, doi: 10.1016/S0016-5085(03)01062-X. 12. Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, et al. Osteoporosis in chronic liver disease: A case-control study. Rheumatol Int. 2009. [Epub ahead of print] 13. Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, et al. Primary biliary cirrhosis and osteoporosis: A case- control study. J Bone Miner Metab. 2008;26:379–84, doi: 10.1007/s00774- 007-0833-1. 14. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43:132-44, doi: 10.1002/hep.21059. 15. Hopf U, Jahn HU, Mo¨ ller B, Stemerowicz R, Wittenbrink C, Klein R, et al. Liver membrane antibodies (LMA) recognize a 26-kD protein on the hepatoceluler surface. Clin Exp Imunol. 1990;79:54–61, doi: 10.1111/j. 1365-2249.1990.tb05126.x. 16. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol. 1984;55:347–54. 17. Teufel A, Galle PR, Kanzler S. Update on autoimmune hepatitis. World J Gastroenterol. 2009;15:1035–41. 18. Pare´s A, Gua n˜abens N. Treatment of bone disorders in liver disease. J Hepatol. 2006;45:445–53. 19. Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003;88:1404–5, doi: 10.1210/jc.2002-021660. 20. Dumitrescu B, van Helden S, ten Broeke R, Nieuwenhuijzen-Kruseman A, Wyers C, Udrea G, et al. Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach. BMC Musculoskelet Disord. 2008;9:109, doi: 10.1186/1471-2474-9-109. 21. Melton LJ III, Atkinson EJ, Khosla S, O’Fallon WM, Riggs BL. Secondary osteoporosis and the risk of vertebral deformities in women. Bone. 1999;24:49–55, doi: 10.1016/S8756-3282(98)00150-1. 22. Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis. 2007;27:161– 72, doi: 10.1055/s-2007-979469. 23. Muro Y. Antinuclear antibodies. Autoimmunity 2005;38:3–9, doi: 10. 1080/08916930400024612. 24. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann NY Acad Sci. 2005;1050:217–28, doi: 10.1196/annals.1313.023. 25. Wiik AS. Anti-nuclear autoantibodies: Clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol. 2005;34: 260–8. 26. Chattopadhyay D, Sen MR, Aryya NC. Immunohistopathological reactions for liver-specific membrane lipo-protein in experimental autoimmune hepatitis. Indian J Pathol Microbiol. 1999;42:291–7. 27. Meyer zum B u¨schenfelde KH, Manns M, H u¨tteroth TH, Hopf U, Arnold W. LM-Ag and LSP—two different target antigens involved in the immunopathogenesis of chronic active hepatitis? Clin Exp Immunol. 1979;37:205–12. 28. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003;37:315–29, doi: 10.1097/ 00004836-200310000-00011. 29. Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Anti- mitochondrial antibodies and other antibodies in primary biliary cirrhosis: Diagnostic and prognostic value. Clin Liver Dis. 2008;12:261–76, doi: 10. 1016/j.cld.2008.02.009. 30. Kumagi T, Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis. 2008;12:243–59, doi: 10.1016/ j.cld.2008.02.014. 31. Jamal SA, Leiter RE, Bavoumi AM, Bauer DC, Cummings SR. Clinical utility of laboratory testing in women with osteoporosis. Osteoporosis Int. 2005;16:534–40, doi: 10.1007/s00198-004-1718-y. 974